We are pleased to read the views of Srinivas Reddy, director, Hetero Pharma in the Economic Times, today. Compulsory licensing hit India’s image: Hetero Pharma . In what is seen as an encouraging and refreshing stands adopted by an Indian drug maker over intellectual property (IP), Hyderabad based Hetero Pharma said that the country has lost nearly $10 billion worth of investment by not respecting IP norms.